Biopharmaceuticals developer Aslan Pharmaceuticals, which counts AMT, Accuron and Tianda as backers, has filed to raise up to $86.3m in an initial public offering.
Singapore-based oncology drug developer Aslan Pharmaceuticals filed for an $86.3m initial public offering on Monday that will enable contract manufacturer Advanced Materials Technologies (AMT) to exit.
Aslan is working on treatments for cancer as well as orphan conditions in the United States and Europe, and diseases that are highly prevalent in Asia. Its lead program, varlitinib, is a growth factor receptor inhibitor intended to treat biliary tract cancer and gastric cancer.
The IPO proceeds will fund global and Chinese…
